
|Videos|June 15, 2011
Dr. Chapman Describes Recent Melanoma Advances
Author(s)Paul Chapman, MD
Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances
Advertisement
Paul Chapman, MD, From Memorial Sloan-Kettering Cancer Center describes recent melanoma advances.
Dr. Chapman says there are now two drugs that improve survival in patients with metastatic melanoma. He adds that this has never happened before in melanoma because only two years ago there was no drug that was shown to improve survival in patients. He says physicians now have choices. While the drugs still need to be improved, they are a start and something that can be built upon in terms of combination therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































